On the public citation graph
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
0 signed · 241 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/hep.26988openalex-snapshot
Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis
inferredcites →https://doi.org/10.1002/hep.29367openalex-snapshot
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
inferredcites →https://doi.org/10.1007/s00535-016-1200-6openalex-snapshot
Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long–Evans Tokushima fatty rats
inferredcites →https://doi.org/10.1007/s00535-017-1364-8openalex-snapshot
Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
inferredcites →https://doi.org/10.1007/s11901-014-0229-3openalex-snapshot
Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1016/j.cmet.2016.02.005openalex-snapshot
Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity
inferredcites →https://doi.org/10.1016/j.curtheres.2017.07.002openalex-snapshot
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
inferredcites →https://doi.org/10.1016/j.diabet.2015.10.003openalex-snapshot
Effect of canagliflozin on liver function tests in patients with type 2 diabetes
inferredcites →https://doi.org/10.1016/j.ecl.2016.06.005openalex-snapshot
Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1016/j.ejphar.2014.01.040openalex-snapshot
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
inferredcites →https://doi.org/10.1016/j.ejphar.2015.02.009openalex-snapshot
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats
inferredcites →https://doi.org/10.1016/j.jceh.2015.02.005openalex-snapshot
Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice
inferredcites →https://doi.org/10.1016/s0140-6736(15)00803-xopenalex-snapshot
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
inferredcites →https://doi.org/10.1021/ac990724xopenalex-snapshot
Quantitation of Monosaccharide Isotopic Enrichment in Physiologic Fluids by Electron Ionization or Negative Chemical Ionization GC/MS Using Di-O-isopropylidene Derivatives
inferredcites →https://doi.org/10.1038/nrneph.2016.170openalex-snapshot
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
inferredcites →https://doi.org/10.1038/nutd.2014.20openalex-snapshot
Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
inferredcites →https://doi.org/10.1053/j.gastro.2015.04.005openalex-snapshot
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1055/s-0042-111515openalex-snapshot
Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa060326openalex-snapshot
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1056/nejmoa1504720openalex-snapshot
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1611925openalex-snapshot
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
inferredcites →https://doi.org/10.1080/14656566.2017.1363888openalex-snapshot
Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
inferredcites →https://doi.org/10.1111/dom.12751openalex-snapshot
Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes
inferredcites →https://doi.org/10.1111/dom.13061openalex-snapshot
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective randomized controlled pilot study
inferredcites →https://doi.org/10.1172/jci112886openalex-snapshot
Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp.
inferredcites →https://doi.org/10.1186/s13098-015-0102-8openalex-snapshot
Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
inferredcites →https://doi.org/10.1186/s13098-016-0169-xopenalex-snapshot
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
inferredcites →https://doi.org/10.1210/jc.2011-2260openalex-snapshot
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
inferredcites →https://doi.org/10.1210/jc.2015-1966openalex-snapshot
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
inferredcites →https://doi.org/10.1371/journal.pone.0151511openalex-snapshot
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
inferredcites →https://doi.org/10.2337/dc10-0856openalex-snapshot
Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc11-1849openalex-snapshot
Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
inferredcites →https://doi.org/10.2337/dc15-0642openalex-snapshot
Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
inferredcites →https://doi.org/10.2337/dc15-1876openalex-snapshot
Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc16-0873openalex-snapshot
Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum
inferredcites →https://doi.org/10.2337/dc16-1787openalex-snapshot
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
inferredcites →https://doi.org/10.2337/dc17-0518openalex-snapshot
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
inferredcites →https://doi.org/10.2337/dc18-0165openalex-snapshot
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
inferredcites →https://doi.org/10.2337/diab.41.3.368openalex-snapshot
Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance
inferredcites →https://doi.org/10.3390/ijms19010137openalex-snapshot
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice
inferredcites →https://doi.org/10.7326/m15-1774openalex-snapshot
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4840179openalex-extracted
The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
inferred← citeshttps://doi.org/10.1002/9781118976074.ch24openalex-snapshot
Non‐alcoholic liver disease (NAFLD)
inferred← citeshttps://doi.org/10.1002/dmrr.3413openalex-snapshot
Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
inferred← citeshttps://doi.org/10.1002/dmrr.3668openalex-snapshot
Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis
inferred← citeshttps://doi.org/10.1002/hep.30670openalex-snapshot
Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1002/hep4.1696openalex-snapshot
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
inferred← citeshttps://doi.org/10.1002/hep4.1993openalex-snapshot
Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
inferred← citeshttps://doi.org/10.1002/jgh3.12274openalex-snapshot
Sodium‐glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin‐resistant patients without type 2 diabetes
inferred← citeshttps://doi.org/10.1002/oby.70134openalex-snapshot
Dapagliflozin‐Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/s00125-021-05442-2openalex-snapshot
Liver-targeting drugs and their effect on blood glucose and hepatic lipids
inferred← citeshttps://doi.org/10.1007/s00125-026-06870-8openalex-snapshot
Comparative hepatic effectiveness of empagliflozin vs dapagliflozin among individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease
inferred← citeshttps://doi.org/10.1007/s10620-025-09464-3openalex-snapshot
The Emerging Therapeutic Promise of SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1007/s11428-020-00599-7openalex-snapshot
Empagliflozin senkt effektiv den Leberfettgehalt bei gut kontrolliertem Typ-2-Diabetes
inferred← citeshttps://doi.org/10.1007/s11428-020-00649-0openalex-snapshot
Nichtalkoholische Fettlebererkrankung und Typ‑2‑Diabetes
inferred← citeshttps://doi.org/10.1007/s11892-020-01349-1openalex-snapshot
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1007/s11892-021-01383-7openalex-snapshot
The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
inferred← citeshttps://doi.org/10.1007/s11892-024-01558-yopenalex-snapshot
NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
inferred← citeshttps://doi.org/10.1007/s12020-025-04493-4openalex-snapshot
Impact of empagliflozin on liver fat reduction in type 2 diabetes and NAFLD: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s12072-020-10094-2openalex-snapshot
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
inferred← citeshttps://doi.org/10.1007/s12072-024-10698-yopenalex-snapshot
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
inferred← citeshttps://doi.org/10.1007/s12072-024-10774-3openalex-snapshot
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
inferred← citeshttps://doi.org/10.1007/s13679-022-00474-0openalex-snapshot
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1007/s40519-021-01287-1openalex-snapshot
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
inferred← citeshttps://doi.org/10.1007/s42000-023-00493-zopenalex-snapshot
Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1016/b978-0-12-822186-0.00006-7openalex-snapshot
Obesity in relation to cardiorenal function
inferred← citeshttps://doi.org/10.1016/b978-0-323-88426-6.00017-8openalex-snapshot
Nonalcoholic fatty liver disease: What comes before and what are the consequences?
inferred← citeshttps://doi.org/10.1016/b978-0-323-99649-5.00013-3openalex-snapshot
Pharmacologic treatment of NAFLD/NASH and their related comorbidities
inferred← citeshttps://doi.org/10.1016/b978-0-323-99649-5.00019-4openalex-snapshot
Clinical management of MASLD and MASH—An overview
inferred← citeshttps://doi.org/10.1016/b978-0-443-27370-4.00023-8openalex-snapshot
Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis
inferred← citeshttps://doi.org/10.1016/j.advms.2024.09.001openalex-snapshot
Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors
inferred← citeshttps://doi.org/10.1016/j.amjms.2023.11.007openalex-snapshot
Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting
inferred← citeshttps://doi.org/10.1016/j.aohep.2020.09.006openalex-snapshot
Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.aohep.2024.101765openalex-snapshot
Effect of bariatric endoscopy on liver fibrosis and steatosis and the course of NAFLD – a prospective interventional study
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2022.07.010openalex-snapshot
Impact of NAFLD and its pharmacotherapy on lipid profile and CVD
inferred← citeshttps://doi.org/10.1016/j.bbrc.2021.04.012openalex-snapshot
Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2
inferred← citeshttps://doi.org/10.1016/j.beem.2026.102107openalex-snapshot
Lean metabolic dysfunction-associated steatotic liver disease: Current insights and knowledge gaps
inferred← citeshttps://doi.org/10.1016/j.cgh.2020.05.021openalex-snapshot
SGLT2 Inhibitors in Liver Patients
inferred← citeshttps://doi.org/10.1016/j.cld.2023.01.002openalex-snapshot
Metabolic Syndrome and Its Association with Nonalcoholic Steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.cld.2023.01.008openalex-snapshot
Current Treatment Options, Including Diet, Exercise, and Medications
inferred← citeshttps://doi.org/10.1016/j.cld.2025.12.003openalex-snapshot
Metabolic Liver Disease Beyond the Liver
inferred← citeshttps://doi.org/10.1016/j.clinthera.2021.07.013openalex-snapshot
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1016/j.diabet.2019.12.007openalex-snapshot
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
inferred← citeshttps://doi.org/10.1016/j.diabet.2020.101215openalex-snapshot
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
inferred← citeshttps://doi.org/10.1016/j.diabet.2025.101709openalex-snapshot
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
inferred← citeshttps://doi.org/10.1016/j.diabres.2024.111846openalex-snapshot
Diabetes as a risk factor for MASH progression
inferred← citeshttps://doi.org/10.1016/j.dld.2021.04.029openalex-snapshot
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
inferred← citeshttps://doi.org/10.1016/j.dsx.2020.11.015openalex-snapshot
Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.dsx.2021.102232openalex-snapshot
Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome
inferred← citeshttps://doi.org/10.1016/j.dsx.2022.102446openalex-snapshot
Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis
inferred← citeshttps://doi.org/10.1016/j.ejphar.2021.174272openalex-snapshot
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.eprac.2022.03.010openalex-snapshot
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
inferred← citeshttps://doi.org/10.1016/j.gastre.2022.12.010openalex-snapshot
NAFLD and type 2 diabetes: A practical guide for the joint management
inferred← citeshttps://doi.org/10.1016/j.gastre.2025.502442openalex-snapshot
Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
inferred← citeshttps://doi.org/10.1016/j.gastre.2026.502639openalex-snapshot
Corrigendum. Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
inferred← citeshttps://doi.org/10.1016/j.gastrohep.2022.12.002openalex-snapshot
NAFLD and type 2 diabetes: A practical guide for the joint management
inferred← citeshttps://doi.org/10.1016/j.gastrohep.2025.502442openalex-snapshot
Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
inferred← citeshttps://doi.org/10.1016/j.gastrohep.2025.502639openalex-snapshot
Corrigendum. Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.12.045openalex-snapshot
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
inferred← citeshttps://doi.org/10.1016/j.jhepr.2019.07.002openalex-snapshot
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
inferred← citeshttps://doi.org/10.1016/j.jhepr.2025.101421openalex-snapshot
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
inferred← citeshttps://doi.org/10.1016/j.lfs.2024.122934openalex-snapshot
Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives
inferred← citeshttps://doi.org/10.1016/j.metabol.2019.07.009openalex-snapshot
Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
inferred← citeshttps://doi.org/10.1016/j.metabol.2019.154001openalex-snapshot
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
inferred← citeshttps://doi.org/10.1016/j.metabol.2020.154203openalex-snapshot
Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.metabol.2020.154299openalex-snapshot
Metabolic liver disease in diabetes – From mechanisms to clinical trials
inferred← citeshttps://doi.org/10.1016/j.metabol.2021.154892openalex-snapshot
Insulin resistance and insulin sensitizing agents
inferred← citeshttps://doi.org/10.1016/j.metabol.2021.154925openalex-snapshot
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.metabol.2024.155937openalex-snapshot
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
inferred← citeshttps://doi.org/10.1016/j.metop.2025.100424openalex-snapshot
Close multilevel links between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1016/j.mmm.2023.03.007openalex-snapshot
Voies thérapeutiques dans l’hépatopathie stéatosique métabolique
inferred← citeshttps://doi.org/10.1016/j.mmm.2026.06.013openalex-snapshot
Prise en charge des patients atteints de diabète de type 2 et de MASLD : synthèse et position commune selon l’AFEF et la SFD
inferred← citeshttps://doi.org/10.1016/j.molmet.2020.101122openalex-snapshot
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
inferred← citeshttps://doi.org/10.1016/j.numecd.2021.04.028openalex-snapshot
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
inferred← citeshttps://doi.org/10.1016/j.numecd.2022.12.010openalex-snapshot
Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent
inferred← citeshttps://doi.org/10.1016/j.tem.2022.03.005openalex-snapshot
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
inferred← citeshttps://doi.org/10.1016/s2213-8587(21)00295-3openalex-snapshot
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
inferred← citeshttps://doi.org/10.1016/s2468-1253(21)00261-2openalex-snapshot
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
inferred← citeshttps://doi.org/10.1016/s2468-1253(24)00310-8openalex-snapshot
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease
inferred← citeshttps://doi.org/10.1038/s41574-021-00507-zopenalex-snapshot
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1038/s41575-021-00448-yopenalex-snapshot
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
inferred← citeshttps://doi.org/10.1038/s41598-022-05704-yopenalex-snapshot
The sodium–glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1038/s41598-022-06402-5openalex-snapshot
Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatments
inferred← citeshttps://doi.org/10.1038/s41598-024-79428-6openalex-snapshot
Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
inferred← citeshttps://doi.org/10.1038/s44324-025-00068-zopenalex-snapshot
SGLT2 inhibitors across various patient populations in the era of precision medicine: the multidisciplinary team approach
inferred← citeshttps://doi.org/10.1053/j.gastro.2021.07.049openalex-snapshot
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1053/j.gastro.2026.01.047openalex-snapshot
Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1055/a-1880-2283openalex-snapshot
Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
inferred← citeshttps://doi.org/10.1055/a-1880-2388openalex-snapshot
Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF Registration No.: 021–025
inferred← citeshttps://doi.org/10.1055/a-2338-9261openalex-snapshot
Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets
inferred← citeshttps://doi.org/10.1080/00325481.2024.2325332openalex-snapshot
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
inferred← citeshttps://doi.org/10.1080/03007995.2021.1965563openalex-snapshot
Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity
inferred← citeshttps://doi.org/10.1080/13543784.2021.1951701openalex-snapshot
Anti-diabetic drugs and NASH: from current options to promising perspectives
inferred← citeshttps://doi.org/10.1080/14656566.2021.1967319openalex-snapshot
Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?
inferred← citeshttps://doi.org/10.1097/cm9.0000000000002091openalex-snapshot
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
inferred← citeshttps://doi.org/10.1097/cm9.0000000000003859openalex-snapshot
Sodium-glucose cotransporter 2 inhibitors facilitate cell phenotype conversion of alpha cells through progenitors to beta cells by activating Ppargc1α in diabetic mice
inferred← citeshttps://doi.org/10.1097/crd.0000000000000537openalex-snapshot
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association
inferred← citeshttps://doi.org/10.1097/hep.0000000000000323openalex-snapshot
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1097/hep.0000000000000855openalex-snapshot
Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial
inferred← citeshttps://doi.org/10.1097/hep.0000000000001371openalex-snapshot
Metabolic reprogramming of immune cells in MASH
inferred← citeshttps://doi.org/10.1097/mpg.0000000000003919openalex-snapshot
Updates in Metabolic Dysfunction‐Associated Fatty Liver Disease (MAFLD) in Children
inferred← citeshttps://doi.org/10.1097/tp.0000000000003867openalex-snapshot
Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients
inferred← citeshttps://doi.org/10.1111/apt.15935openalex-snapshot
Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1111/dme.14356openalex-snapshot
Mechanisms, screening modalities and treatment options for individuals with non‐alcoholic fatty liver disease and type 2 diabetes
inferred← citeshttps://doi.org/10.1111/dom.14484openalex-snapshot
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications
inferred← citeshttps://doi.org/10.1111/dom.14651openalex-snapshot
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
inferred← citeshttps://doi.org/10.1111/dom.14955openalex-snapshot
Validation of a diet‐induced Macaca fascicularis model of non‐alcoholic steatohepatitis with dietary and pioglitazone interventions
inferred← citeshttps://doi.org/10.1111/dom.16198openalex-snapshot
Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study
inferred← citeshttps://doi.org/10.1111/eci.70003openalex-snapshot
Pharmacological treatment options for metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review
inferred← citeshttps://doi.org/10.1111/hepr.13645openalex-snapshot
Meta‐analysis of the effect of sodium–glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1111/jgh.15202openalex-snapshot
The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1111/liv.14350openalex-snapshot
A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions
inferred← citeshttps://doi.org/10.1111/liv.14799openalex-snapshot
Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis
inferred← citeshttps://doi.org/10.1111/liv.15404openalex-snapshot
Management of NAFLD in primary care settings
inferred← citeshttps://doi.org/10.1111/liv.70747openalex-snapshot
Global Prevalence, Incidence, and Outcomes of Coexisting MASLD and Chronic Kidney Disease: A Meta‐Analysis
inferred← citeshttps://doi.org/10.1136/bmj.m4747openalex-snapshot
Management of non-alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1136/bmjdrc-2020-001990openalex-snapshot
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
inferred← citeshttps://doi.org/10.1136/flgastro-2024-102856openalex-snapshot
Role of anti-diabetic medications in the management of MASLD
inferred← citeshttps://doi.org/10.1146/annurev-physiol-022724-105515openalex-snapshot
At the Crossroads of Health and Disease: Consequences of Fat in the Liver
inferred← citeshttps://doi.org/10.1155/ije/5558442openalex-snapshot
Empagliflozin in the Absence of Diabetes: A Systematic Review of Its Anthropometric and Metabolic Effects in Humans and Animals
inferred← citeshttps://doi.org/10.1161/atvbaha.119.311904openalex-snapshot
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?
inferred← citeshttps://doi.org/10.1161/circulationaha.124.070535openalex-snapshot
Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach
inferred← citeshttps://doi.org/10.1177/30502071231220779openalex-snapshot
Diagnosis and Management of MASLD: An Metabolic Perspective of a Multisystem Disease
inferred← citeshttps://doi.org/10.1186/s12916-020-01787-4openalex-snapshot
Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus
inferred← citeshttps://doi.org/10.1186/s12933-022-01589-3openalex-snapshot
Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial
inferred← citeshttps://doi.org/10.1186/s12986-024-00871-3openalex-snapshot
Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)
inferred← citeshttps://doi.org/10.1186/s13578-024-01267-9openalex-snapshot
New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease
inferred← citeshttps://doi.org/10.1210/clinem/dgac591openalex-snapshot
Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1210/clinem/dgac624openalex-snapshot
Approach to the Patient With Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1210/clinem/dgad249openalex-snapshot
Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS
inferred← citeshttps://doi.org/10.1210/endocr/bqab157openalex-snapshot
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
inferred← citeshttps://doi.org/10.1210/endrev/bnag022openalex-snapshot
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
inferred← citeshttps://doi.org/10.1210/endrev/bnz009openalex-snapshot
Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management
inferred← citeshttps://doi.org/10.14218/jcth.2024.00123openalex-snapshot
Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.14341/dm12848openalex-snapshot
Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board
inferred← citeshttps://doi.org/10.14341/dm13340openalex-snapshot
Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
inferred← citeshttps://doi.org/10.14740/jem632openalex-snapshot
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Hepatic Fibrosis in Patients With Type 2 Diabetes: A Chart-Based Analysis
inferred← citeshttps://doi.org/10.14740/jem942openalex-snapshot
Pharmacological Treatment of Diabetes Mellitus: An Overview of New Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Diabetes Mellitus
inferred← citeshttps://doi.org/10.15277/bjd.2020.258openalex-snapshot
Effects of canagliflozin are mostly observed at first follow-up, within 6 months of commencement: results for the ABCD canagliflozin audit
inferred← citeshttps://doi.org/10.1556/650.2022.32480openalex-snapshot
A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség.
inferred← citeshttps://doi.org/10.15829/1728-8800-2024-3996openalex-snapshot
Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
inferred← citeshttps://doi.org/10.15829/2713-0177-2023-17openalex-snapshot
Type 2 diabetes mellitus, non-alcoholic fatty liver disease and cardiovascular disease: causal relationships and the role of anti-diabetic drugs
inferred← citeshttps://doi.org/10.17116/dokgastro202312041103openalex-snapshot
Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.18699/ssmj20220601openalex-snapshot
Potential new application points of SGLT2 inhibitors in patients with heart failure in combination with diabetes mellitus, non-alcoholic fatty liver disease and anemia (literature review)
inferred← citeshttps://doi.org/10.21203/rs.3.rs-882630/v1openalex-snapshot
The Effect of Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on Insulin Resistance, Hepatic Insulin Clearance, Beta-Cell Function in the Japanese Patients with type 2 Diabetes
inferred← citeshttps://doi.org/10.2147/dmso.s528569openalex-snapshot
The Emerging Role of Anti-Hyperglycemic Agents for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.2174/1568026623666230714113808openalex-snapshot
Emerging Therapies and Therapeutic Targets for Composite Liver Disease: NASH
inferred← citeshttps://doi.org/10.2174/1573402116999201209203534openalex-snapshot
Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
inferred← citeshttps://doi.org/10.22141/2224-0721.22.3.2026.1717openalex-snapshot
Impact of modern glucose-lowering therapies on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes
inferred← citeshttps://doi.org/10.2337/dc19-0641openalex-snapshot
Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
inferred← citeshttps://doi.org/10.2337/dc20-2887openalex-snapshot
Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial
inferred← citeshttps://doi.org/10.2337/dc21-1136openalex-snapshot
Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
inferred← citeshttps://doi.org/10.2337/dc21-2049openalex-snapshot
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial
inferred← citeshttps://doi.org/10.2337/dc23-1646openalex-snapshot
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes
inferred← citeshttps://doi.org/10.2337/dc23-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
inferred← citeshttps://doi.org/10.2337/dc24-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
inferred← citeshttps://doi.org/10.2337/dc25-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025
inferred← citeshttps://doi.org/10.2337/dc26-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026
inferred← citeshttps://doi.org/10.2337/dci19-0064openalex-snapshot
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
inferred← citeshttps://doi.org/10.2337/dsi23-0012openalex-snapshot
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
inferred← citeshttps://doi.org/10.31083/rcm51234openalex-snapshot
Metabolic Dysfunction–Associated Steatotic Liver Disease as a Systemic Driver of Heart Failure With Preserved Ejection Fraction: Mechanistic Insights and Emerging Therapeutic Perspectives
inferred← citeshttps://doi.org/10.31146/1682-8658-ecg-240-8-110-118openalex-snapshot
Oral Hypoglycemic Therapy in Metabolic Dysfunction-Associated Fatty Liver Disease
inferred← citeshttps://doi.org/10.32689/2663-0672-2023-4-9openalex-snapshot
STEATOSIC LIVER DISEASE AND CARDIOVASCULAR DISEASES: ASSOCIATION, PROGNOSIS AND TREATMENT
inferred← citeshttps://doi.org/10.3350/cmh.2020.0137openalex-snapshot
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.3350/cmh.2025.0825openalex-snapshot
Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis
inferred← citeshttps://doi.org/10.3389/fendo.2023.1193373openalex-snapshot
Uncoupling hepatic insulin resistance – hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes
inferred← citeshttps://doi.org/10.3390/biom15030324openalex-snapshot
Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment
inferred← citeshttps://doi.org/10.3390/diabetology6040023openalex-snapshot
Metabolic-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes: Mechanisms, Diagnostic Approaches, and Therapeutic Interventions
inferred← citeshttps://doi.org/10.3390/endocrines6020027openalex-snapshot
Current and Emerging Treatments for Metabolic Associated Steatotic Liver Disease and Diabetes: A Narrative Review
inferred← citeshttps://doi.org/10.3390/ijms21165820openalex-snapshot
Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
inferred← citeshttps://doi.org/10.3390/ijms22063062openalex-snapshot
Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class
inferred← citeshttps://doi.org/10.3390/jcm11175144openalex-snapshot
Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus—From Prevalence to Diagnostic Approach and Treatment Strategies
inferred← citeshttps://doi.org/10.3390/jcm12206561openalex-snapshot
Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy
inferred← citeshttps://doi.org/10.3390/jcm14020428openalex-snapshot
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
inferred← citeshttps://doi.org/10.3390/jpm11060499openalex-snapshot
Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
inferred← citeshttps://doi.org/10.3390/livers3040040openalex-snapshot
Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
inferred← citeshttps://doi.org/10.3390/medicina59061136openalex-snapshot
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.3390/metabo11010022openalex-snapshot
Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.3390/metabo13040517openalex-snapshot
Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes
inferred← citeshttps://doi.org/10.35401/2541-9897-2025-10-1-101-109openalex-snapshot
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
inferred← citeshttps://doi.org/10.3803/enm.2022.102openalex-snapshot
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
inferred← citeshttps://doi.org/10.4093/dmj.2020.0010openalex-snapshot
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
inferred← citeshttps://doi.org/10.4093/jkd.2022.23.2.83openalex-snapshot
Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
inferred← citeshttps://doi.org/10.4236/jbm.2024.121011openalex-snapshot
Progress in the Study of the Hepatoprotective Effect of SGLT2i on NAFLD Patients with T2DM
inferred← citeshttps://doi.org/10.4254/wjh.v12.i9.533openalex-snapshot
Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
inferred← citeshttps://doi.org/10.4254/wjh.v14.i9.1718openalex-snapshot
Therapies for non-alcoholic fatty liver disease: A 2022 update
inferred← citeshttps://doi.org/10.47749/t/unicamp.2021.1265511openalex-snapshot
Efeitos de diferentes protocolos de treinamento físico em vias biomoleculares de controle de produção hepática de glicose e metabolismo lipídico no fígado de roedores obesos
inferred← citeshttps://doi.org/10.5005/jp-journals-10054-0265openalex-snapshot
Evaluation of Clinical Efficacy of Smart Insulin for Diabetes Management: A Systematic Review
inferred← citeshttps://doi.org/10.52787/zojs3069openalex-snapshot
Hígado graso no alcohólico: certezas e incertidumbres de una epidemia silenciosa
inferred← citeshttps://doi.org/10.53590/japt.02.1030openalex-snapshot
Nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.57105/2415-7252-2023-5-01openalex-snapshot
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
inferred← citeshttps://doi.org/10.58837/chula.the.2019.370openalex-snapshot
Effect of Canagliflozin on liver steatosis in obese non diabetic patients with non-alcoholicfatty liver disease: A double blind randomized controlled trial
inferred← citeshttps://doi.org/10.59715/pntjmp.1.4.7openalex-snapshot
Hướng dẫn của Hiệp hội Nghiên cứu bệnh gan Châu Á Thái Bình Dương trong chẩn đoán và điều trị bệnh gan nhiễm mỡ liên quan chuyển hóa
inferred← citeshttps://doi.org/10.6084/m9.figshare.20454856openalex-snapshot
Additional file 1 of Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial
inferred← citeshttps://doi.org/10.69860/nobel.9786053359111.7openalex-snapshot
Diabetes Mellitus and Non-alcoholic Fatty Liver Disease (NAFLD)
inferred← citeshttps://doi.org/10.70749/ijbr.v3i2.663openalex-snapshot
Beyond Glucose: Empagliflozin’s Impact on Fatty Liver in Patients with Type 2 Diabetes; A True Game Changer
inferred← citeshttps://doi.org/10.7570/jomes.2019.28.1.18openalex-snapshot
The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
inferred← citeshttps://doi.org/10.7570/jomes23052openalex-snapshot
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
inferred← citeshttps://doi.org/10.7759/cureus.76716openalex-snapshot
Targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Available and Future Pharmaceutical Options
inferred← citeshttps://doi.org/10.7759/cureus.90205openalex-snapshot
Empagliflozin Treatment for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.